/VIR
VIR Stock - Vir Biotechnology, Inc.
Healthcare|BiotechnologyNASDAQ
$5.76-2.87%
$0.17 (-2.87%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.49
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.66
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+177.8%upside
Target: $16.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VIR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.70 – $5.82
TARGET (TP)$16.00
STOP LOSS$5.30
RISK/REWARD1:22.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.34
52W High$14.45
52W Low$4.16
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $74.20M | $86.18M | $1.62B | $1.10B | $67.25M |
| Gross Profit | $-404,440,000 | $-486,647,000 | $994.83M | $581.54M | $67.25M |
| Gross Margin | -545.0% | -564.7% | 61.6% | 53.1% | 100.0% |
| Operating Income | $-587,165,000 | $-684,305,000 | $833.07M | $420.75M | $-296,980,000 |
| Net Income | $-521,960,000 | $-615,061,000 | $515.84M | $528.58M | $-298,665,000 |
| Net Margin | -703.4% | -713.7% | 31.9% | 48.3% | -444.1% |
| EPS | $-3.83 | $-4.59 | $3.89 | $4.07 | $-2.51 |
Company Overview
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
57%
Hold / Neutral
3
43%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
4 Bullish3 Neutral/Bearish
Price Targets
$25
Average Target
↑ 326.3% Upside
Now
$9
Low
$25
Average
$53
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 3rd 2025 | Evercore ISI | Initiation | Outperform | $12 |
| August 27th 2025 | BofA Securities | Upgrade | Buy | $14 |
| January 29th 2024 | JP Morgan | Downgrade | Neutral | $9← $23 |
| September 8th 2023 | BofA Securities | Downgrade | Neutral | $14← $23 |
| March 6th 2023 | JP Morgan | Upgrade | Overweight | $34← $35 |
| February 21st 2023 | Goldman | Upgrade | Buy | $53← $41 |
| January 27th 2023 | Morgan Stanley | Upgrade | Equal Weight | $30← $18 |
| September 14th 2022 | SVB Leerink | Initiation | Outperform | $40 |
| September 9th 2022 | Morgan Stanley | Initiation | Underweight | $15 |
Earnings History & Surprises
VIRBeat Rate
44%
Last 18 quarters
Avg Surprise
+221.0%
EPS vs Estimate
Beats / Misses
8/10
Last 12 quarters
Latest EPS
$-1.17
Q4 2025
EPS Surprise History
Q1 24
+24.6%
$-0.86vs$-1.14
Q2 24
+51.5%
$-0.48vs$-0.99
Q3 24
-9.7%
$-1.02vs$-0.93
Q4 24
-62.5%
$-1.56vs$-0.96
Q1 25
+10.6%
$-0.76vs$-0.85
Q2 25
-6.0%
$-0.88vs$-0.83
Q3 25
-11.1%
$-0.80vs$-0.72
Q4 25
-67.1%
$-1.17vs$-0.70
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.52 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.70 | $-1.17 | -67.1% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.72 | $-0.80 | -11.1% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-0.83 | $-0.88 | -6.0% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $-0.85 | $-0.76 | +10.6% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $-0.96 | $-1.56 | -62.5% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.93 | $-1.02 | -9.7% | ✗ MISS |
Q2 2024 | May 2, 2024 | $-0.99 | $-0.48 | +51.5% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-1.14 | $-0.86 | +24.6% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-1.21 | $-1.22 | -0.8% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-1.21 | $-1.45 | -19.8% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.81 | $-1.06 | -30.9% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-0.39 | $-0.76 | -92.4% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.21 | $1.30 | +719.0% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.17 | $-0.58 | -241.2% | ✗ MISS |
Q2 2022 | May 5, 2022 | $3.78 | $3.85 | +1.9% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $3.04 | $3.92 | +28.9% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $0.02 | $0.82 | +3487.1% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.48 | $0.46 | +195.8% | ✓ BEAT |
Latest News
Vir Biotechnology Licenses Hepatitis Delta Therapy To Norgine In Up To €550 Million Deal, Secures €55 Million Upfront, And Up To €495 Million In Clinical, Regulatory And Sales Milestones, Along With Tiered, Mid-Teen To High-Twenties Percent Royalties On Net Sales
📈 PositiveBenzinga•Dec 16, 2025, 09:07 PM
Reported Earlier, Vir Biotechnology Announces Phase 2 Data Showing Tobevibart And Elebsiran Combination Achieves 66% Undetectable HDV RNA At Week 48 With Favorable Safety
📈 PositiveBenzinga•Nov 10, 2025, 07:27 AM
Vir Biotechnology Q3 EPS $(1.17) Misses $(0.84) Estimate, Sales $240.000K Miss $1.983M Estimate
📉 NegativeBenzinga•Nov 5, 2025, 09:17 PM
Vir Biotechnology Completes Enrollment In ECLIPSE 1 Phase 3 Trial For Chronic Hepatitis Delta
📈 PositiveBenzinga•Nov 3, 2025, 01:07 PM
Vir Biotechnology Doses First Patient In Phase 1 Trial Of Dual-Masked T-Cell Engager VIR-5500 For Prostate Cancer
📈 PositiveBenzinga•Oct 9, 2025, 08:09 PM
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $15 Price Target
📈 PositiveBenzinga•Sep 15, 2025, 06:39 PM
Evercore ISI Group Initiates Coverage On Vir Biotechnology with Outperform Rating, Announces Price Target of $12
📈 PositiveBenzinga•Sep 3, 2025, 01:34 PM
Vir Biotechnology shares are trading higher after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $12 to $14.
📈 PositiveBenzinga•Aug 27, 2025, 04:04 PM
Vir upgraded at BoA on potential for liver disease asset; shares surge 13%
📈 PositiveSeeking Alpha•Aug 27, 2025, 03:54 PM
B of A Securities Upgrades Vir Biotechnology to Buy, Raises Price Target to $14
📈 PositiveBenzinga•Aug 27, 2025, 03:49 PM
Frequently Asked Questions about VIR
What is VIR's current stock price?
Vir Biotechnology, Inc. (VIR) is currently trading at $5.76 per share. The stock has moved -2.87% today.
What is the analyst price target for VIR?
The average analyst price target for VIR is $16.00, based on 1 analyst.
What sector is Vir Biotechnology, Inc. in?
Vir Biotechnology, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VIR's market cap?
Vir Biotechnology, Inc. has a market capitalization of $0.80 billion, making it a small-cap company.
Does VIR pay dividends?
No, Vir Biotechnology, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorDAWN
Day One Biopharmaceuticals, Inc.
$9.24
Mkt Cap: $0.9B
DNA
Ginkgo Bioworks Holdings, Inc.
$8.10
Mkt Cap: $0.4B
GERN
Geron Corporation
$1.33
Mkt Cap: $0.8B
IOVA
Iovance Biotherapeutics, Inc.
$2.48
Mkt Cap: $0.8B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
LENZ
LENZ Therapeutics, Inc.
$18.00
Mkt Cap: $0.5B
MRVI
Maravai LifeSciences Holdings, Inc.
$3.43
Mkt Cap: $0.5B
PRME
Prime Medicine, Inc.
$3.64
Mkt Cap: $0.6B
REPL
Replimune Group, Inc.
$9.88
Mkt Cap: $0.8B
YDES
YD Bio Limited Ordinary Shares
$12.38
Mkt Cap: $0.9B
Explore stocks similar to VIR for comparison